Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.

Dettagli Bibliografici
Autori principali:	Moorthy, V, McConkey, S, Roberts, M, Gothard, P, Arulanantham, N, Degano, P, Schneider, J, Hannan, C, Roy, M, Gilbert, S, Peto, T, Hill, A
Natura:	Journal article
Lingua:	English
Pubblicazione:	2003

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
di: Moorthy, V, et al.
Pubblicazione: (2003)

Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
di: Webster, D, et al.
Pubblicazione: (2006)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
di: McConkey, S, et al.
Pubblicazione: (2003)

Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models.
di: Dégano, P, et al.
Pubblicazione: (1999)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
di: Moorthy, V, et al.
Pubblicazione: (2003)

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.
di: Webster, D, et al.
Pubblicazione: (2005)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
di: Gilbert, S, et al.
Pubblicazione: (1999)

Therapeutic vaccination against hepatitis B virus using heterolgous prime boost strategy with DNA and modified vaccinia virus ankara vectors
di: McConkey, S, et al.
Pubblicazione: (2003)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
di: Schneider, J, et al.
Pubblicazione: (1998)

Clinical development of Modified Vaccinia virus Ankara vaccines.
di: Gilbert, S
Pubblicazione: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
di: Gilbert, S
Pubblicazione: (2013)

A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees.
di: Schneider, J, et al.
Pubblicazione: (2001)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
di: Alharbi, N, et al.
Pubblicazione: (2015)

DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy.
di: Hill, A, et al.
Pubblicazione: (2000)

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.
di: Dunachie, S, et al.
Pubblicazione: (2006)

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.
di: Reyes-Sandoval, A, et al.
Pubblicazione: (2010)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
di: Behboudi, S, et al.
Pubblicazione: (2004)

Erratum: Prime-boost immunization with adenoviral and modified vaccinia virus ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses
di: Reyes-Sandoval, A, et al.
Pubblicazione: (2011)

Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.
di: Bejon, P, et al.
Pubblicazione: (2006)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.
di: Naif Khalaf Alharbi, et al.
Pubblicazione: (2015-01-01)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
di: Cottingham, M, et al.
Pubblicazione: (2008)

Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.
di: Walther, M, et al.
Pubblicazione: (2006)

Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay.
di: Winstone, N, et al.
Pubblicazione: (2009)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
di: Matthew G Cottingham, et al.
Pubblicazione: (2008-02-01)

Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria.
di: Keating, S, et al.
Pubblicazione: (2005)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
di: Caroline Staib, et al.
Pubblicazione: (2003-04-01)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
di: Olga Vladimirovna Orlova, et al.
Pubblicazione: (2022-09-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
di: Volker Sandig, et al.
Pubblicazione: (2013-11-01)

Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8(+) T-Cell Responses, (vol 78, pg 152, 2010)
di: Reyes-Sandoval, A, et al.
Pubblicazione: (2011)

Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya
di: Bejon, P, et al.
Pubblicazione: (2006)

Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.
di: Bejon, P, et al.
Pubblicazione: (2006)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA).
di: Matthew G. Cottingham, et al.
Pubblicazione: (2011-01-01)

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.
di: Gilbert, S, et al.
Pubblicazione: (2006)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
di: Hanke, T, et al.
Pubblicazione: (1998)

Population pharmacokinetics of halofantrine in healthy volunteers and patients with symptomatic falciparum malaria
di: Klein, K, et al.
Pubblicazione: (2012)

Population pharmacokinetics of halofantrine in healthy volunteers and patients with symptomatic falciparum malaria.
di: Klein, K, et al.
Pubblicazione: (2012)

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
di: Smith, C, et al.
Pubblicazione: (2005)

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
di: Goonetilleke, N, et al.
Pubblicazione: (2003)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
di: Mcshane, H, et al.
Pubblicazione: (2001)

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP
di: Rampling, T, et al.
Pubblicazione: (2016)

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.

Documenti analoghi

Documenti analoghi